nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefuroxime—Cutaneous vasculitis—Hydrochlorothiazide—nephrolithiasis	0.0442	0.106	CcSEcCtD
Cefuroxime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0389	0.0665	CbGpPWpGaD
Cefuroxime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.0361	0.0617	CbGpPWpGaD
Cefuroxime—Stiffness—Hydrochlorothiazide—nephrolithiasis	0.0304	0.0731	CcSEcCtD
Cefuroxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.025	0.0428	CbGpPWpGaD
Cefuroxime—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.0244	0.0418	CbGpPWpGaD
Cefuroxime—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.0235	0.0567	CcSEcCtD
Cefuroxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.0232	0.0397	CbGpPWpGaD
Cefuroxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.0229	0.0392	CbGpPWpGaD
Cefuroxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.0229	0.0392	CbGpPWpGaD
Cefuroxime—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.0227	0.0388	CbGpPWpGaD
Cefuroxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.0213	0.0363	CbGpPWpGaD
Cefuroxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.0213	0.0363	CbGpPWpGaD
Cefuroxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.0174	0.0297	CbGpPWpGaD
Cefuroxime—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.0171	0.0412	CcSEcCtD
Cefuroxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.0161	0.0276	CbGpPWpGaD
Cefuroxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.0161	0.0275	CbGpPWpGaD
Cefuroxime—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.0151	0.0363	CcSEcCtD
Cefuroxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.015	0.0256	CbGpPWpGaD
Cefuroxime—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.0144	0.0246	CbGpPWpGaD
Cefuroxime—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.0133	0.0228	CbGpPWpGaD
Cefuroxime—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.0129	0.031	CcSEcCtD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0112	0.0191	CbGpPWpGaD
Cefuroxime—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0262	CcSEcCtD
Cefuroxime—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0261	CcSEcCtD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.0104	0.0178	CbGpPWpGaD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0102	0.0175	CbGpPWpGaD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0102	0.0175	CbGpPWpGaD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0095	0.0162	CbGpPWpGaD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0095	0.0162	CbGpPWpGaD
Cefuroxime—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00928	0.0223	CcSEcCtD
Cefuroxime—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0088	0.0212	CcSEcCtD
Cefuroxime—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.0088	0.0212	CcSEcCtD
Cefuroxime—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00785	0.0189	CcSEcCtD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00776	0.0133	CbGpPWpGaD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00776	0.0133	CbGpPWpGaD
Cefuroxime—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00754	0.0182	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00754	0.0182	CcSEcCtD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00721	0.0123	CbGpPWpGaD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00721	0.0123	CbGpPWpGaD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.0072	0.0123	CbGpPWpGaD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.0072	0.0123	CbGpPWpGaD
Cefuroxime—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00677	0.0163	CcSEcCtD
Cefuroxime—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00677	0.0163	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00673	0.0162	CcSEcCtD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00669	0.0114	CbGpPWpGaD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00669	0.0114	CbGpPWpGaD
Cefuroxime—SLC15A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00643	0.011	CbGpPWpGaD
Cefuroxime—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.0064	0.0154	CcSEcCtD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00638	0.0109	CbGpPWpGaD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00638	0.0109	CbGpPWpGaD
Cefuroxime—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00635	0.0153	CcSEcCtD
Cefuroxime—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00629	0.0152	CcSEcCtD
Cefuroxime—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00628	0.0151	CcSEcCtD
Cefuroxime—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00619	0.0149	CcSEcCtD
Cefuroxime—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00606	0.0146	CcSEcCtD
Cefuroxime—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00602	0.0145	CcSEcCtD
Cefuroxime—SLC15A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00597	0.0102	CbGpPWpGaD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00592	0.0101	CbGpPWpGaD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00592	0.0101	CbGpPWpGaD
Cefuroxime—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.0058	0.014	CcSEcCtD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00569	0.00972	CbGpPWpGaD
Cefuroxime—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00548	0.0132	CcSEcCtD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00528	0.00903	CbGpPWpGaD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.0052	0.00889	CbGpPWpGaD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.0052	0.00889	CbGpPWpGaD
Cefuroxime—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00505	0.0121	CcSEcCtD
Cefuroxime—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00497	0.012	CcSEcCtD
Cefuroxime—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00485	0.0117	CcSEcCtD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00483	0.00825	CbGpPWpGaD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00483	0.00825	CbGpPWpGaD
Cefuroxime—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00464	0.0112	CcSEcCtD
Cefuroxime—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00461	0.0111	CcSEcCtD
Cefuroxime—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00452	0.0109	CcSEcCtD
Cefuroxime—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00446	0.0107	CcSEcCtD
Cefuroxime—Cough—Hydrochlorothiazide—nephrolithiasis	0.0044	0.0106	CcSEcCtD
Cefuroxime—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.0043	0.0103	CcSEcCtD
Cefuroxime—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.0043	0.0103	CcSEcCtD
Cefuroxime—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00412	0.00992	CcSEcCtD
Cefuroxime—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00403	0.00971	CcSEcCtD
Cefuroxime—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00402	0.00968	CcSEcCtD
Cefuroxime—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00398	0.00959	CcSEcCtD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00394	0.00674	CbGpPWpGaD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00394	0.00674	CbGpPWpGaD
Cefuroxime—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00392	0.00945	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00375	0.00903	CcSEcCtD
Cefuroxime—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00367	0.00884	CcSEcCtD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00366	0.00627	CbGpPWpGaD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00366	0.00627	CbGpPWpGaD
Cefuroxime—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00366	0.00881	CcSEcCtD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00366	0.00626	CbGpPWpGaD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00366	0.00626	CbGpPWpGaD
Cefuroxime—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00362	0.00873	CcSEcCtD
Cefuroxime—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00862	CcSEcCtD
Cefuroxime—Pain—Hydrochlorothiazide—nephrolithiasis	0.00352	0.00848	CcSEcCtD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.0034	0.00582	CbGpPWpGaD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.0034	0.00582	CbGpPWpGaD
Cefuroxime—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00337	0.00811	CcSEcCtD
Cefuroxime—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00788	CcSEcCtD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00327	0.00559	CbGpPWpGaD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00327	0.00559	CbGpPWpGaD
Cefuroxime—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00784	CcSEcCtD
Cefuroxime—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00784	CcSEcCtD
Cefuroxime—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00303	0.00731	CcSEcCtD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00303	0.00518	CbGpPWpGaD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00303	0.00518	CbGpPWpGaD
Cefuroxime—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00291	0.00702	CcSEcCtD
Cefuroxime—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00282	0.00678	CcSEcCtD
Cefuroxime—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00272	0.00656	CcSEcCtD
Cefuroxime—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00262	0.0063	CcSEcCtD
Cefuroxime—SLC15A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00261	0.00447	CbGpPWpGaD
Cefuroxime—Rash—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00625	CcSEcCtD
Cefuroxime—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00259	0.00625	CcSEcCtD
Cefuroxime—Headache—Hydrochlorothiazide—nephrolithiasis	0.00258	0.00621	CcSEcCtD
Cefuroxime—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00589	CcSEcCtD
Cefuroxime—SLC15A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00242	0.00414	CbGpPWpGaD
